Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 241 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Control Form 6 Clear all
Terminated Phase 2 Interventional

Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis

NCT01659138
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
SAR339658, Placebo
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
25
States / cities
Sun City, Arizona • Mission Hills, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 31, 2026, 1:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia

NCT04013555
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
N-acetylcysteine (NAC), Placebo, Tryptophan
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 31, 2026, 1:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers

NCT05462132
View directory record Official record
Conditions
Homocystinuria
Interventions
SYNB1353
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 64 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 31, 2026, 1:16 AM EDT
Withdrawn Phase 2 Interventional

Study of BXCL501 In Agitation Associated With Delirium in ICU Patients

NCT05313386
View directory record Official record
Conditions
Agitation, Delirium
Interventions
BXCL501, Placebo film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 31, 2026, 1:16 AM EDT
Completed Phase 2 Interventional

Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis

NCT04002934
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Bazedoxifene Acetate
Drug
Lead sponsor
Riley Bove, MD
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 31, 2026, 1:16 AM EDT
Completed Phase 4 Interventional

Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses

NCT04276259
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
Buprenorphine, Naltrexone, Oral Placebo, IM Placebo, Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.
Drug · Device
Lead sponsor
Marta Peciña, MD PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 31, 2026, 1:16 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Preemptive Ibuprofen Effects on Pain Perception Following Extraction and Bone Graft

NCT05919745
View directory record Official record
Conditions
Pain, Post Operative, Quality of Life
Interventions
Ibuprofen 600 mg, Placebo, Acetaminophen
Drug
Lead sponsor
Marquette University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 31, 2026, 1:16 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma

NCT00393796
View directory record Official record
Conditions
Bladder Cancer
Interventions
SUTENT, Placebo
Drug · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 31, 2026, 1:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects

NCT04505397
View directory record Official record
Conditions
Healthy
Interventions
SKL24741, Placebo
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 31, 2026, 1:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Calm 2: A Study of Health and Wellness Products on Feelings of Anxiety, Stress, and Health Outcomes

NCT05837910
View directory record Official record
Conditions
Anxiety, Stress
Interventions
Calm Active Study Product 1.1 Usage, Calm Active Study Product 1.2 Usage, Calm Active Study Product 1.3 Usage, Placebo Control Form 1, Placebo Control Form 2, Calm Active Study Product 2.1 Usage, Placebo Control Form 3, Calm Active Study Product 3.1 Usage, Placebo Control Form 4, Calm Active Study Product 4.1 Usage
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
3,853 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 31, 2026, 1:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults

NCT01578889
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-MAG vaccine, IL-12 pDNA adjuvant, VSV HIV gag vaccine, Placebo, Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device
Biological · Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
5
States / cities
New York, New York • Rochester, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 31, 2026, 1:16 AM EDT
Recruiting Phase 2 Interventional

Confirmatory Clinical Study in Active Ulcerative Colitis

NCT07296315
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Low-dose MH002, High-dose MH002, Placebo
Drug
Lead sponsor
MRM Health NV
Industry
Eligibility
16 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Miami, Florida • Orlando, Florida • Palmetto Bay, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 31, 2026, 1:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

NCT01852266
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV cps2 Vaccine, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Laurel, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 31, 2026, 1:16 AM EDT
Completed Phase 1 Interventional

Vancomycin for the Treatment of NAAT(+)/Toxin(-) C. Difficile

NCT03827447
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Vancomycin Oral Capsule, Placebo Oral Capsule
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 31, 2026, 1:16 AM EDT
Completed Phase 3 Interventional

Pharmacological and Behavioral Treatment After Bariatric Surgery

NCT05157698
View directory record Official record
Conditions
Obesity
Interventions
Naltrexone and Bupropion Combination, Behavioral Weight Loss, Placebo
Drug · Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 31, 2026, 1:16 AM EDT
Completed Phase 3 Interventional Results available

First Time Use of SD-809 in Huntington Disease

NCT01795859
View directory record Official record
Conditions
Chorea
Interventions
SD-809, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 31, 2026, 1:16 AM EDT
Active, not recruiting Phase 1 Interventional

Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in PAH.

NCT07751120
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
MTT with antibiotic preconditioning + fiber supplementation, MTT with antibiotic preconditioning + placebo supplementation, MTT with placebo + placebo supplementation.
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 31, 2026, 1:16 AM EDT
Completed Phase 2 Interventional

Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)

NCT05717062
View directory record Official record
Conditions
Snakebite, Envenoming, Snake
Interventions
Varespladib intravenous form, varespladib-methyl- oral form, Placebo intravenous form, Placebo - oral form
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Phoenix, Arizona • Tucson, Arizona • Palm Springs, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 31, 2026, 1:16 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder

NCT07193563
View directory record Official record
Conditions
Social Anxiety Disorder (SAD)
Interventions
ENX-102, Placebo
Drug · Other
Lead sponsor
Engrail Therapeutics INC
Industry
Eligibility
18 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 31, 2026, 1:16 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers

NCT03077477
View directory record Official record
Conditions
Neoplasms, Medication Toxicity, Tolerance
Interventions
AMXT 1501, Placebo Oral Tablet
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 31, 2026, 1:16 AM EDT
Terminated Phase 3 Interventional Results available

Effect of Efpeglenatide on Cardiovascular Outcomes

NCT03496298
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Efpeglenatide (SAR439977), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
4,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
79
States / cities
Sheffield, Alabama • Gilbert, Arizona • Surprise, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 31, 2026, 1:16 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits

NCT00487942
View directory record Official record
Conditions
Schizophrenia
Interventions
armodafinil, placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
12
States / cities
Garden Grove, California • National City, California • Paramount, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 31, 2026, 1:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Energy2: A Study of Health and Wellness Products on Fatigue and Other Health Outcomes

NCT06074627
View directory record Official record
Conditions
Fatigue, Energy
Interventions
Energy Placebo Control Form 1, Energy Active Study Product 1.1 Usage, Energy Active Study Product 1.2 Usage, Energy Active Study Product 1.3 Usage
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
1,189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 31, 2026, 1:16 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure

NCT03292653
View directory record Official record
Conditions
Cardiac Failure Aggravated
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
La Jolla, California • New Haven, Connecticut • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 31, 2026, 1:16 AM EDT